Spirea
Rakesh Dixit, Ph.D., DABT, is a highly experienced biopharmaceutical executive with extensive expertise in biologics, drug development, and toxicology. Currently serving as Co-founder, President, and CSO of Regio Biosciences, a biotechnology company focused on innovative biologics for cardiometabolic diseases and cancers, Rakesh also holds the position of President and CEO at Bionavigen, specializing in biologics, cell and gene therapy, and small molecule drug development. As the Global Head of Biologics Safety Assessment at MedImmune and previously at AstraZeneca, Rakesh managed various aspects of research and development, while earlier roles at Johnson & Johnson and Merck involved project management and toxicology. Rakesh holds a Ph.D. in Toxicology/Pharmacology from Case Western Reserve University School of Medicine.
This person is not in the org chart
This person is not in any offices
Spirea
Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.